The Growing List for our Q&A:
I wanted to say in question 5 that KERN got there by nefarious methods through a SPAC, but I'm trying to be nice. I'm practicing for my New Years Resolution coming up.
I merged and consolidated some of KMP's and Global's questions together as there was some overlap.
We can add to this and/or edit before final submission. As a group/team effort. And I intend to present it that way in email, as a group of 3 investors, or whatever that number climbs to, that have presented all their questions in one email. And this can keep the Q&A good with substance for a full hour or whatever time we have if nobody asks questions live. And hopefully that happens too.
And if the answers are good, I can have good fodder to go beat over the heads of KERN shareholders with since they are feeling some pain right now. I'd love to have the opportunity to kick them when they are down. New Years Resolution doesn't start yet...
1) A year or so ago, there was mention of a dual listing on the Sedar exchange. Can you explain why that plan was dropped, and do you have any plans to do that in the future?
2) In the last conference call, you said, "We're already seeing substantially improved offerings of finance that we hope to report positively on in the Q2 call." Would you be able to elaborate on that some?
3) Between July and August, there were 500,000 extra shares added to the OS. I feel like they were from conversions. It hurts to see. I worry about excessive dilution at these prices, but what is your thoughts on that? Am I looking at it wrong, and how do you see the future in terms of that?
4) Would it be fair to say that MJ Freeway and BioTrack are direct competitors? Do you see it that way? And if so, do they win contracts because of lower pricing? It seems to me that their margins are lower, and I'm wondering if that's because they are undercutting you in price. Am I understanding that correctly? Their stock is higher than ours, and I'm wondering what your thoughts are on the reasons behind that.
5) Does Helix have plans to uplist in the future? Akerna (KERN) seems to have gotten on the Nasdaq by way of a SPAC. If so, do you have a plan, as it's my understanding that we do not currently meet the requirements? And would a reverse split ever be considered in such a plan?
6) Can you shed any light on what the sale of the guard side of Helix would mean to to your bottom line, and will that be reflected in the next quarter? Do you have a projection of what your gross revenue and margins will look like at years' end without the security business?
7) How much of your revenue is recurring, and what are your recurring growth expectations?
